Back to Search
Start Over
Evaluating immune responses after sipuleucel-T therapy.
- Source :
-
Cancer biology & therapy [Cancer Biol Ther] 2015; Vol. 16 (8), pp. 1119-21. Date of Electronic Publication: 2015 Jun 08. - Publication Year :
- 2015
-
Abstract
- Following FDA approval of sipuleucel-T in 2010 for metastatic castration resistant prostate cancer (mCRPC), several studies have described the effect of sipuleucel-T on peripheral immune responses. Retrospective associations have also been made with immune responses and survival. A recently published study by Fong et al. was the first to characterize the immune response of sipuleucel-T in the tumor microenvironment. The findings of this study have been hypothesis generating, yet it remains unclear whether the peri-tumor immune response described is predictive of survival. Increasing evidence suggests that radiographic or PSA progression does not accurately reflect survival with sipuleucel-T and other immunotherapies. Finding an immune biomarker which can accurately reflect clinical benefit and validating it prospectively offers the potential for a predictive indicator of response in an area where none currently exists.
- Subjects :
- Cancer Vaccines immunology
Clinical Trials as Topic
Humans
Male
Prostatic Neoplasms, Castration-Resistant immunology
Prostatic Neoplasms, Castration-Resistant pathology
Survival Rate
Tissue Extracts pharmacology
Tumor Microenvironment
Cancer Vaccines therapeutic use
Prostatic Neoplasms, Castration-Resistant drug therapy
Prostatic Neoplasms, Castration-Resistant mortality
Tissue Extracts immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1555-8576
- Volume :
- 16
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Cancer biology & therapy
- Publication Type :
- Academic Journal
- Accession number :
- 26054644
- Full Text :
- https://doi.org/10.1080/15384047.2015.1056417